A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

Focal Laser Ablation System Receives FDA Approval – Ablates Soft Tissue in a Physician’s Office Requiring No General Anesthesia

December 16, 2020

Focal laser ablation system is designed to ablate soft tissue in a physician’s office. It uses a proprietary laser needle and a thermal optical sensor to precisely target and treats soft tissue while minimizing the impact on healthy tissues states Avenda Health. The company will focus its commercialization efforts on urology applications.

“We purposely designed our therapy system to be simple and intuitive to use in a physician’s office. Given the current strain on the healthcare system due to COVID-19, we believe it is vital for more therapies to move from the hospital setting to an office-based procedure,” states Dr. Brittany Berry-Pusey, co-founder and COO of Avenda Health.

“This device is backed by over a decade of research. With our first FDA clearance, we are now able to offer this revolutionary technology to patients and will quickly be following up with additional technologies from our pipeline including an investigational version that is being used in clinical trials for the treatment of intermediate-risk prostate cancer,” said Dr. Shyam Natarajan, co-founder, and CEO of Avenda Health.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy